135 related articles for article (PubMed ID: 37556775)
1. Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial.
Pfeiler G; Hlauschek D; Mayer EL; Deutschmann C; Kacerovsky-Strobl S; Martin M; Meisel JL; Zdenkowski N; Loibl S; Balic M; Park H; Prat A; Isaacs C; Bajetta E; Balko JM; Bellet-Ezquerra M; Bliss J; Burstein H; Cardoso F; Fohler H; Foukakis T; Gelmon KA; Goetz M; Haddad TC; Iwata H; Jassem J; Lee SC; Linderholm B; Los M; Mamounas EP; Miller KD; Morris PG; Munzone E; Gal-Yam EN; Ring A; Shepherd L; Singer C; Thomssen C; Tseng LM; Valagussa P; Winer EP; Wolff AC; Zoppoli G; Machacek-Link J; Schurmans C; Huang X; Gauthier E; Fesl C; Dueck AC; DeMichele A; Gnant M;
J Clin Oncol; 2023 Nov; 41(33):5118-5130. PubMed ID: 37556775
[TBL] [Abstract][Full Text] [Related]
2. Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).
Mayer EL; Fesl C; Hlauschek D; Garcia-Estevez L; Burstein HJ; Zdenkowski N; Wette V; Miller KD; Balic M; Mayer IA; Cameron D; Winer EP; Ponce Lorenzo JJ; Lake D; Pristauz-Telsnigg G; Haddad TC; Shepherd L; Iwata H; Goetz M; Cardoso F; Traina TA; Sabanathan D; Breitenstein U; Ackerl K; Metzger Filho O; Zehetner K; Solomon K; El-Abed S; Theall KP; Lu DR; Dueck A; Gnant M; DeMichele A
J Clin Oncol; 2022 Feb; 40(5):449-458. PubMed ID: 34995105
[TBL] [Abstract][Full Text] [Related]
3. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.
Mayer EL; Dueck AC; Martin M; Rubovszky G; Burstein HJ; Bellet-Ezquerra M; Miller KD; Zdenkowski N; Winer EP; Pfeiler G; Goetz M; Ruiz-Borrego M; Anderson D; Nowecki Z; Loibl S; Moulder S; Ring A; Fitzal F; Traina T; Chan A; Rugo HS; Lemieux J; Henao F; Lyss A; Antolin Novoa S; Wolff AC; Vetter M; Egle D; Morris PG; Mamounas EP; Gil-Gil MJ; Prat A; Fohler H; Metzger Filho O; Schwarz M; DuFrane C; Fumagalli D; Theall KP; Lu DR; Bartlett CH; Koehler M; Fesl C; DeMichele A; Gnant M
Lancet Oncol; 2021 Feb; 22(2):212-222. PubMed ID: 33460574
[TBL] [Abstract][Full Text] [Related]
4. Impact of body mass index on pathological response after neoadjuvant chemotherapy: results from the I-SPY 2 trial.
Wang H; Yee D; Potter D; Jewett P; Yau C; Beckwith H; Watson A; O'Grady N; Wilson A; Brain S; Pohlmann P; ; Blaes A
Breast Cancer Res Treat; 2024 Apr; 204(3):589-597. PubMed ID: 38216819
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).
Gnant M; Dueck AC; Frantal S; Martin M; Burstein HJ; Greil R; Fox P; Wolff AC; Chan A; Winer EP; Pfeiler G; Miller KD; Colleoni M; Suga JM; Rubovsky G; Bliss JM; Mayer IA; Singer CF; Nowecki Z; Hahn O; Thomson J; Wolmark N; Amillano K; Rugo HS; Steger GG; Hernando Fernández de Aránguiz B; Haddad TC; Perelló A; Bellet M; Fohler H; Metzger Filho O; Jallitsch-Halper A; Solomon K; Schurmans C; Theall KP; Lu DR; Tenner K; Fesl C; DeMichele A; Mayer EL;
J Clin Oncol; 2022 Jan; 40(3):282-293. PubMed ID: 34874182
[TBL] [Abstract][Full Text] [Related]
6. Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial.
Di Cosimo S; Porcu L; Agbor-Tarh D; Cinieri S; Franzoi MA; De Santis MC; Saura C; Huober J; Fumagalli D; Izquierdo M; Piccart M; Daidone MG; de Azambuja E
Breast Cancer Res; 2020 Oct; 22(1):115. PubMed ID: 33109233
[TBL] [Abstract][Full Text] [Related]
7. A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma.
Mayer EL; DeMichele A; Rugo HS; Miller K; Waks AG; Come SE; Mulvey T; Jeselsohn R; Overmoyer B; Guo H; Barry WT; Huang Bartlett C; Koehler M; Winer EP; Burstein HJ
Ann Oncol; 2019 Sep; 30(9):1514-1520. PubMed ID: 31250880
[TBL] [Abstract][Full Text] [Related]
8. Febrile Neutropenia Rates According to Body Mass Index and Dose Capping in Women Receiving Chemotherapy for Early Breast Cancer.
Lote H; Sharp A; Redana S; Papadimitraki E; Capelan M; Ring A
Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):597-603. PubMed ID: 26936608
[TBL] [Abstract][Full Text] [Related]
9. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
[TBL] [Abstract][Full Text] [Related]
10. Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer.
Lynce F; Blackburn MJ; Zhuo R; Gallagher C; Hahn OM; Abu-Khalaf M; Mohebtash M; Wu T; Pohlmann PR; Dilawari A; Tiwari SR; Chitalia A; Warren R; Tan M; Shajahan-Haq AN; Isaacs C
Cancer; 2021 Oct; 127(19):3622-3630. PubMed ID: 34157782
[TBL] [Abstract][Full Text] [Related]
11. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).
Verma S; Bartlett CH; Schnell P; DeMichele AM; Loi S; Ro J; Colleoni M; Iwata H; Harbeck N; Cristofanilli M; Zhang K; Thiele A; Turner NC; Rugo HS
Oncologist; 2016 Oct; 21(10):1165-1175. PubMed ID: 27368881
[TBL] [Abstract][Full Text] [Related]
12. Neutropenia management with palbociclib in Japanese patients with advanced breast cancer.
Masuda N; Mukai H; Inoue K; Rai Y; Ohno S; Mori Y; Hashigaki S; Muramatsu Y; Umeyama Y; Iwata H; Toi M
Breast Cancer; 2019 Sep; 26(5):637-650. PubMed ID: 31127500
[TBL] [Abstract][Full Text] [Related]
13. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.
Finn RS; Crown JP; Ettl J; Schmidt M; Bondarenko IM; Lang I; Pinter T; Boer K; Patel R; Randolph S; Kim ST; Huang X; Schnell P; Nadanaciva S; Bartlett CH; Slamon DJ
Breast Cancer Res; 2016 Jun; 18(1):67. PubMed ID: 27349747
[TBL] [Abstract][Full Text] [Related]
15. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
Cristofanilli M; Turner NC; Bondarenko I; Ro J; Im SA; Masuda N; Colleoni M; DeMichele A; Loi S; Verma S; Iwata H; Harbeck N; Zhang K; Theall KP; Jiang Y; Bartlett CH; Koehler M; Slamon D
Lancet Oncol; 2016 Apr; 17(4):425-439. PubMed ID: 26947331
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure.
Roncato R; Peruzzi E; Gerratana L; Posocco B; Nuzzo S; Montico M; Orleni M; Corsetti S; Bartoletti M; Gagno S; Canil G; De Mattia E; Angelini J; Baraldo M; Puglisi F; Cecchin E; Toffoli G
Biomed Pharmacother; 2023 Aug; 164():114906. PubMed ID: 37295250
[TBL] [Abstract][Full Text] [Related]
17. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
Turner NC; Ro J; André F; Loi S; Verma S; Iwata H; Harbeck N; Loibl S; Huang Bartlett C; Zhang K; Giorgetti C; Randolph S; Koehler M; Cristofanilli M;
N Engl J Med; 2015 Jul; 373(3):209-19. PubMed ID: 26030518
[TBL] [Abstract][Full Text] [Related]
18. Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial.
Martel S; Lambertini M; Agbor-Tarh D; Ponde NF; Gombos A; Paterson V; Hilbers F; Korde L; Manukyants A; Dueck A; Maurer C; Piccart M; Moreno-Aspitia A; Desmedt C; Di Cosimo S; de Azambuja E
J Natl Compr Canc Netw; 2021 Jan; 19(2):181-189. PubMed ID: 33401235
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3.
Iwata H; Umeyama Y; Liu Y; Zhang Z; Schnell P; Mori Y; Fletcher O; Marshall JC; Johnson JG; Wood LS; Toi M; Finn RS; Turner NC; Bartlett CH; Cristofanilli M
Oncologist; 2021 Jul; 26(7):e1143-e1155. PubMed ID: 33955129
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up.
Finn RS; Rugo HS; Gelmon KA; Cristofanilli M; Colleoni M; Loi S; Schnell P; Lu DR; Theall KP; Mori A; Gauthier E; Bananis E; Turner NC; Diéras V
Oncologist; 2021 May; 26(5):e749-e755. PubMed ID: 33486783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
